MX2021013275A - Terapia genica intratecal e intravenosa para el tratamiento de la enfermedad de batten infantil. - Google Patents
Terapia genica intratecal e intravenosa para el tratamiento de la enfermedad de batten infantil.Info
- Publication number
- MX2021013275A MX2021013275A MX2021013275A MX2021013275A MX2021013275A MX 2021013275 A MX2021013275 A MX 2021013275A MX 2021013275 A MX2021013275 A MX 2021013275A MX 2021013275 A MX2021013275 A MX 2021013275A MX 2021013275 A MX2021013275 A MX 2021013275A
- Authority
- MX
- Mexico
- Prior art keywords
- polynucleotide
- intrathecal
- disease
- treatment
- gene therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840360P | 2019-04-29 | 2019-04-29 | |
| PCT/US2020/030427 WO2020223322A1 (en) | 2019-04-29 | 2020-04-29 | Intrathecal and intravenous combination gene therapy for the treatment of infantile batten disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013275A true MX2021013275A (es) | 2022-03-17 |
Family
ID=73029200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013275A MX2021013275A (es) | 2019-04-29 | 2020-04-29 | Terapia genica intratecal e intravenosa para el tratamiento de la enfermedad de batten infantil. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220193268A1 (enExample) |
| EP (1) | EP3963081A4 (enExample) |
| JP (1) | JP7788594B2 (enExample) |
| KR (1) | KR20220046513A (enExample) |
| CN (1) | CN114269935A (enExample) |
| AU (1) | AU2020264438A1 (enExample) |
| BR (1) | BR112021021632A8 (enExample) |
| CA (1) | CA3138274A1 (enExample) |
| IL (1) | IL287608A (enExample) |
| MX (1) | MX2021013275A (enExample) |
| SG (1) | SG11202111908XA (enExample) |
| WO (1) | WO2020223322A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4551695A1 (en) * | 2022-07-06 | 2025-05-14 | Research Institute at Nationwide Children's Hospital | Adeno-associated virus delivery of cln1 polynucleotide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130010121A (ko) * | 2010-03-23 | 2013-01-25 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
| AU2015364636B9 (en) * | 2014-12-16 | 2021-12-02 | Board Of Regents Of The University Of Nebraska | Gene therapy for Juvenile Batten Disease |
| US11504435B2 (en) * | 2016-06-13 | 2022-11-22 | The University Of North Carolina At Chapel Hill | Optimized CLN1 genes and expression cassettes and their use |
| CN111065741A (zh) * | 2017-07-08 | 2020-04-24 | 吉尼松公司 | 脊髓性肌萎缩症的治疗 |
| US20210115453A1 (en) * | 2017-08-31 | 2021-04-22 | Poseida Therapeutics, Inc. | Transposon system and methods of use |
-
2020
- 2020-04-29 AU AU2020264438A patent/AU2020264438A1/en active Pending
- 2020-04-29 MX MX2021013275A patent/MX2021013275A/es unknown
- 2020-04-29 US US17/607,315 patent/US20220193268A1/en active Pending
- 2020-04-29 CN CN202080047719.4A patent/CN114269935A/zh active Pending
- 2020-04-29 CA CA3138274A patent/CA3138274A1/en not_active Abandoned
- 2020-04-29 WO PCT/US2020/030427 patent/WO2020223322A1/en not_active Ceased
- 2020-04-29 BR BR112021021632A patent/BR112021021632A8/pt not_active Application Discontinuation
- 2020-04-29 SG SG11202111908XA patent/SG11202111908XA/en unknown
- 2020-04-29 KR KR1020217038864A patent/KR20220046513A/ko not_active Withdrawn
- 2020-04-29 EP EP20798198.6A patent/EP3963081A4/en active Pending
- 2020-04-29 JP JP2021564486A patent/JP7788594B2/ja active Active
-
2021
- 2021-10-27 IL IL287608A patent/IL287608A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202111908XA (en) | 2021-11-29 |
| KR20220046513A (ko) | 2022-04-14 |
| BR112021021632A8 (pt) | 2022-06-28 |
| JP7788594B2 (ja) | 2025-12-19 |
| EP3963081A4 (en) | 2023-07-26 |
| AU2020264438A1 (en) | 2021-12-16 |
| BR112021021632A2 (enExample) | 2021-12-21 |
| WO2020223322A1 (en) | 2020-11-05 |
| CA3138274A1 (en) | 2020-11-05 |
| EP3963081A1 (en) | 2022-03-09 |
| IL287608A (en) | 2021-12-01 |
| JP2022530264A (ja) | 2022-06-28 |
| CN114269935A (zh) | 2022-04-01 |
| US20220193268A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004501A (es) | Clasificacion de microambientes tumorales. | |
| MX2019014412A (es) | Productos terapeuticos para la enfermedad de almacenamiento de glucogeno de tipo iii. | |
| CY1119295T1 (el) | Γονιδιακη θεραπεια για ασθενειες λυσοσωμικης αποθhκευσης | |
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| BR112022002609A2 (pt) | Métodos de tratamento de tumores estromais gastrointestinais | |
| CY1115617T1 (el) | Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer | |
| MX2024008350A (es) | Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla. | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| Watanabe et al. | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: a phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan | |
| EA202090564A1 (ru) | Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри | |
| MX382778B (es) | Metodos para tratar cancer pancreatico | |
| Wang et al. | Systemic administration of attenuated Salmonella typhimurium in combination with interleukin-21 for cancer therapy | |
| MX2021008081A (es) | Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa. | |
| EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
| BR112022008164A2 (pt) | Terapia de combinação para tratar câncer cerebral | |
| MX2021013275A (es) | Terapia genica intratecal e intravenosa para el tratamiento de la enfermedad de batten infantil. | |
| EA202090558A1 (ru) | Схемы лечения | |
| MX2019008076A (es) | Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. | |
| MX2021013351A (es) | Terapias de combinacion. | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
| BR112019007028A2 (pt) | métodos e composições farmacêuticas para o tratamento do câncer renal | |
| RU2016138790A (ru) | Композиции на основе сиалированных гликопротеинов и их применение | |
| EA201791442A1 (ru) | Способы лечения гематологических нарушений, солидных опухолей или инфекционных заболеваний с применением естественных клеток-киллеров |